Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10242313 | 0.78 | KDM4E (0.32) | ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL13306829 | 0.78 | — | — | |
| SCHEMBL9108114 | 0.73 | GAA (0.41) | ALDH1A1HPGDKDM4ESMN1; SMN2 | |
| SCHEMBL10350066 | 0.72 | — | — | |
| SCHEMBL8555731 | 0.72 | — | — | |
| SCHEMBL24417705 | 0.70 | ALDH1A1 (0.43) | ALDH1A1HPGDNOS1HSD17B10PIK3CG | |
| SCHEMBL2678408 | 0.70 | NOS1 (0.52) | ALDH1A1HPGDSMN1; SMN2NOS1CYP1A2 | |
| SCHEMBL19486516 | 0.70 | ALDH1A1 (0.43) | ALDH1A1HPGDNOS1HSD17B10PIK3CG | |
| SCHEMBL5537146 | 0.70 | KDM4E (0.34) | ALDH1A1HPGDKDM4ESMN1; SMN2NOS1 | |
| SCHEMBL20791827 | 0.68 | ALDH1A1 (0.42) | ALDH1A1HPGDSMN1; SMN2NOS1PIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180243298-A1 | TRPV3 MODULATORS | ABBVIE INC. | 2018-08-30 | — | — | US | disclosed |
| WO-2016160938-A1 | N-(1,3-THIAZOL-2-YL)PYRIMIDINE-5-CARBOXAMIDES AS TRPV3 MODULATORS | ABBVIE INC. (US) | 2016-10-06 | — | — | WO | disclosed |
| EP-2880034-B1 | AMINO-HETEROARYL 7-HYDROXY-SPIROPIPERIDINE INDOLINYL ANTAGONISTS OF P2Y1 RECEPTOR | BRISTOL MYERS SQUIBB CO (US) | 2016-06-22 | — | — | EP | disclosed |
| US-9120798-B2 | Amino-heteroaryl 7-hydroxy-spiropiperidine indolinyl antagonists of P2Y1 receptor | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-09-01 | — | — | US | disclosed |
| US-20150197521-A1 | AMINO-HETEROARYL 7-HYDROXY-SPIROPIPERIDINE INDOLINYL ANTAGONISTS OF P2Y1 RECEPTOR | BRISTOL-MYERS SQUIBB COMPANY | 2015-07-16 | — | — | US | disclosed |
| EP-2880034-A1 | AMINO-HETEROARYL 7-HYDROXY-SPIROPIPERIDINE INDOLINYL ANTAGONISTS OF P2Y1 RECEPTOR | Bristol-Myers Squibb Company (US) | 2015-06-10 | — | — | EP | disclosed |
| US-8889670-B2 | Heterocyclic compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-18 | — | — | US | disclosed |
| WO-2014022253-A1 | AMINO-HETEROARYL 7-HYDROXY-SPIROPIPERIDINE INDOLINYL ANTAGONISTS OF P2Y1 RECEPTOR | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-02-06 | — | — | WO | disclosed |
| US-8629157-B2 | Pyrrolidine compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-14 | — | — | US | disclosed |
| US-8273772-B2 | Heteroaryl compounds as P2Y1 receptor inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-09-25 | — | — | US | disclosed |
| US-20060035944-A1 | Remedies for neurodegenerative diseases | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-02-16 | — | — | US | disclosed |
| US-20060019958-A1 | Immunity-related protein kinase inhibitors | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-01-26 | — | — | US | disclosed |
| US-20060014811-A1 | Medicament for treatment of cancer | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-01-19 | — | — | US | disclosed |
| EP-1555018-A1 | REMEDIES FOR NEURODEGENERATIVE DISEASES | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-07-20 | — | — | EP | disclosed |
| EP-1535610-A1 | THERAPEUTIC AGENT FOR CANCER | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-06-01 | — | — | EP | disclosed |
| EP-1535609-A1 | NF-KB ACTIVATION INHIBITORS | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-06-01 | — | — | EP | disclosed |
| EP-1514544-A1 | ANTIALLERGIC | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-16 | — | — | EP | disclosed |
| EP-1512396-A1 | INHIBITORS AGAINST THE ACTIVATION OF AP-1 AND NFAT | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-09 | — | — | EP | disclosed |
| EP-1510210-A1 | IMMUNITY-RELATED PROTEIN KINASE INHIBITORS | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-02 | — | — | EP | disclosed |
| EP-1510207-A1 | THERAPEUTIC DRUG FOR DIABETES | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019958-A1 | Immunity-related protein kinase inhibitors | MAP3K1, MAP3K7, MAP3K8 | ALDH1A1 3396/4885HPGD 981/4885KDM4E 1319/4885 |
| US-20180243298-A1 | TRPV3 MODULATORS | TRPV3, TRPV1, TRPV2 | ALDH1A1 3440/4885HPGD 869/4885KDM4E 4286/4885 |
| US-20060014811-A1 | Medicament for treatment of cancer | HDAC3, HDAC1, HDAC6 | ALDH1A1 97/4885HPGD 738/4885KDM4E 2118/4885 |
| US-20150197521-A1 | AMINO-HETEROARYL 7-HYDROXY-SPIROPIPERIDINE INDOLINYL ANTAGONISTS OF P2Y1 RECEPTOR | P2RY1, P2RY2, P2RY11 | ALDH1A1 580/4885HPGD 381/4885KDM4E 4343/4885 |
| US-20060035944-A1 | Remedies for neurodegenerative diseases | GLA, CHAT, MAPT | ALDH1A1 181/4885HPGD 567/4885KDM4E 2403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.